

COMPANY INFORMATION

Company name	Lasens «Laboratory of sensory systems», LLC (Nizhny Novgorod, Russia)
Project name	<u>ROSE</u>: Diagnostic complex for the early detection of oncological disease
Project leaders	Alexander Zemskov, Viktor Novikov
Contact info	Email: lasens.unn@mail.ru Phone: (831)4623653
Company/project history	Spin-off company of Lobachevsky State University of Nizhni Novgorod, "Lasens ", LLC, established in 2014.

PROJECT INFORMATION

Description of technology/product

Diagnostic complex composed of specially created bio-chips, working together with reagent kit and an optoelectronic detector which uses special software for the registration, processing and analysis of ongoing diagnostics. This process allows for the identification of cancer tests in human blood samples cancer-testis genes mRNA.

Diagrams and photos




Fig.1 Production of the chip with 20 markers of cancer.




Fig. 2 Diagnostic complex "ROSE"

Added value

Our technology uses a highly sensitive detection method to determine even the slightest possibility for either first or second stage cancer detection among the most important oncological diseases. This approach offers an affordable, reliable, high performed and easy to administer and internet form of early stage cancer detection, minimizing the risk of medical mistakes.

Key advantages

- 20 tumor markers on a single chip
- High sensitivity (at least 90%)
- High specificity (at least 99%)
- Low price analysis for the patient (est.) ~ \$ 14.00
- The reasonable cost of the Complex (in RF) - \$ 7,900
- The capacity of 100 chips / hour
- PC control and opto-electronic unit
- Storage of results
- Modifications for fixed and mobile laboratories.

Potential markets

- hospitals; clinical and immunological laboratories of medical institutions in various fields
- institute of medical and biological profile
- Sales (RF, the forecast) - \$ 190 million / year.

Search for contacts

- doctors and biologists
- developers and manufactures of medical equipment/devices
- representatives of insurance companies.

Current status of technology/product

- Fabricated several prototypes of the Diagnostic complex
- Design documentation
- Currently undergoing clinical trials (sampling of more than 150 people). To select the material used hospital in Moscow, Vladimir, Nizhny Novgorod.

Comparison with competitors

- OM-Biochip (Russia) for the simultaneous quantification of 6 markers in comparison with 20 markers of DC "ROSE"
- Luminex (U.S.) for multiplex analysis of tumor markers and growth factors based on the technology of x-MAR - 6 markers in comparison with 20 markers of DC "ROSE".

Scientific publications and patents

- More than 15 articles in national and international journals
- The 2 patents on the detector (Russia)
- Patent Pending on biomarkers (Russia) № 2012144891 from 22.10.12.

Purpose of meeting with partners

- To presentation technology/product to potential customers
- To investigate market
- To find partners and/or investors.